Elicitation and use of patients' preferences in the treatment of psoriasis: A systematic review

Acta Dermato-Venereologica

Volumn 92, Issue 4, 2012, Pages 341-346

  Umar, Nasir ^a   Yamamoto, Shelby ^a   Loerbroks, Adrian ^a   Terris, Darcey ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Patient's involvement; Patient's preferences; Physician patient relations; Psoriasis; Psoriasis arthritis; Shared decision making

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; PSORALEN;

COCHRANE LIBRARY; CREAM; HEALTH STATUS; HUMAN; INFORMATION RETRIEVAL; MEDLINE; OINTMENT; PATIENT DECISION MAKING; PATIENT PREFERENCE; PHOTOTHERAPY; PHYSICIAN; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PSYCINFO; PUBLICATION; PUVA; QUALITY OF LIFE; REVIEW; STANDARD; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS; CHOICE BEHAVIOR; DERMATOLOGIC AGENTS; HUMANS; PATIENT PARTICIPATION; PATIENT PREFERENCE; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; PSORIASIS; PUVA THERAPY;

EID: 84863479745     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1304     Document Type: Review

References (70)

1. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009; 160: 1264-1272.
2. Park JJ, Choi YD, Lee JB, Kim SJ, Lee SC, Won YH, et al. Psoriasiform drug eruption induced by anti-tuberculosis medication: potential role of plasma-cytoid dendritic cells. Acta Derm Venereol 2010; 90: 305-306.
3. Langham S, Langham J, Goertz HP, Ratcliffe M. Large- scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systematic and critical review. BMC Med Res Methodol 2011; 11: 32.
4. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
5. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212: 137-144.
6. National-Psoriasis-Foundation. About psoriasis: statistics. 2008 [cited 2010, 20 December]. Available from: http://www.psoriasis.org/about/stats/.
7. Ashcroft DM, Seston E, Griffiths CEM. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with UK dermatologists. Br J Dermatol 2006; 155: 1236-1241.
8. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
9. Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
10. Olsson J, Terris D, Elg M, Lundberg J, Lindblad S. The one-person randomized controlled trial. Qual Manag Health Care 2005; 14: 206-216.
11. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Der Deutschen Dermatologischen Gesellschaft. 2006; 4 Suppl 2: S1-126.
12. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2011. J Der Deutschen Dermatologischen Gesellschaft 2011; 9 Suppl 2: S1-104.
13. Gokdemir G, Ari S, Koslu A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol 2008; 22: 330-335.
14. Housman TS, Mellen BG, Rapp SR, Fleischer AB, Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002; 70: 327-332.
15. Ross CK, Steward CA, Sinacore JM. The importance of patient preferences in the measurement of health care satisfaction. Med Care 1993; 31: 1138-1149.
16. Opmeer BC, de Borgie CAJM, Mol BWJ, Bossuyt PMM. Assessing preferences regarding healthcare interventions that involved non-health outcomes. The Patient 2010; 3: 1-10.
17. Ryan M, Scott DA, Reeves C, Bate A, Teijlingen V, Russell EM, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001; 5: 1-186.
18. Schiffner R, Landthaler M, Stolz W. Willingness-to-pay and time-trade-off: useful utilities in patients with psoriasis vulgaris? Dermatol Psychosomat 2001; 1: 4.
19. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-557.
20. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. Journal Der Deutschen Dermatologischen Gesellschaft. 2007; 5 Suppl 3: 1-119.
21. Feldman S, Behnam SM, Behnam SE, Koo JY. Involving the patient: impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol 2005; 53 (Suppl 1): S78-85.
22. Loh A, Simon D, Bieber C, Eich W, Harter M. Patient and citizen participation in German health care - current state and future perspectives. Z Arztl Fortbild Qualitatssich 2007; 101: 229-235.
23. Seston EM, Ashcroft DM, Griffiths CEM. Balancing the benefits and risks of drug treatment - A stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007; 143: 1175-1179.
24. Say RE, Thomson R. The importance of patient preferences in treatment decisions - challenges for doctors. BMJ 2003; 327: 5442-5425.
25. Doherty C, Doherty W. Patients' preferences for involvement in clinical decision-making within secondary care and the factors that influence their preferences. J Nurs Manag 2005; 13: 119-127.
26. Lecluse LL, Tutein Nolthenius JL, Bos JD, Spuls PI. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 2009; 160: 1340-1343.
27. McCormack JP, Loewen P. Adding "value" to clinical practice guidelines. Can Fam Physician 2007; 53: 1326-1327.
28. Carlsen B, Aakvik A. Patient involvement in clinical decision making: the effect of GP attitude on patient satisfaction. Health Expect 2006; 9: 1448-1457.
29. van den Brink-Muinen A, van Dulmen SM, de Haes HCJM, Visser AP, Schellevis FG, Bensing JM. Has patients' involvement in the decision-making process changed over time? Health Expect 2006; 9: 333-342.
30. Martin H, Andreas L. Shared decision-making in diverse healthcare systems - translating research and health policy into practice. Patient Educ Couns 2008; 73:399-401.
31. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
32. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. [Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM Statement]. Rev Esp Salud Publica 2000; 74: 107-118 (in Spainsh)
33. CRD. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2009 [accessed 2010, 11 February]. Available from: http://www.yorkacuk/inst/crd/systematic_reviews_book.htm.
34. Schmidt H, Hjorth N, Holm P. A randomized trial on the D-homosteroid domoprednate (Ro 12-7024) in the treatment of dermatoses. Dermatologica 1984; 168: 127-130.
35. Schmidt H, Hjorth N, Holm P. Domoprednate, a new non-halogenated topical steroid - comparison to hydrocortisone butyrate. Dermatologica 1987; 175: 145-147.
36. Berg M. Emollient creams in the treatment of psoriasis - a study of patient preference. Curr Ther Res Clin E 1994; 55: 598-600.
37. van de Kerkhof PCM, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-298.
38. Medansky RS, Cuffie CA, Tanner DJ. Mometasone furoate 0.1% salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Clin Ther 1997; 19: 701-709.
39. Dutz JP, Lui H. A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. Int J Dermatol 1998; 37: 51-53.
40. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-1075.
41. Opmeer BC, Heydendael VMR, Deborgie CAJM, Spuis PI, Bossuyt PMM, Bos JD, et al. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol 2007; 60: 696-703.
42. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. J Eur Acad Dermatol 2000; 14: 153-158.
43. Larkö O. Treatment of psoriasis with a new UVB-lamp. Acta Derm Venereol 1989; 69: 357-359.
44. Cooper EJ, Herd RM, Priestley GC, Hunter JAA. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 2000; 25: 111-114.
45. Cameron H, Dawe RS, Yule S, Murphy J, Ibbotson SH, Ferguson J. A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B photo therapy for chronic plaque psoriasis. Br J Dermatol 2002; 147: 973-978.
46. Qureshi AA, Brandling-Bennett HA, Wittenberg E, Chen SC, Sober AJ, Kvedar JC. Willingness-to-pay stated preferences for telemedicine versus in-person visits in patients with a history of psoriasis or melanoma. Telemed J E-Health 2006; 12: 639-643.
47. Kjaer T, Bech M, Gyrd-Hansen D, Hart-Hansen K. Ordering effect and price sensitivity in discrete choice experiments: need we worry? Health Econ 2006; 15: 1217-1228.
48. Zug KA, Littenberg B, Baughman RD, Kneeland T, Nease RF, Sumner W, et al. Assessing the preferences of patients with psoriasis - a quantitative, utility approach. Arch Dermatol 1995; 131: 561-568.
49. Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008; 158: 351-359.
50. Delfino M, Jr, Holt EW, Taylor CR, Wittenberg E, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008; 59: 439-447.
51. Hu SW, Holt EW, Husni ME, Qureshi AA. Willingness-topay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot study. Semin Arthritis Rheum 2010; 39: 384-397.
52. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003; 148: 1153-1160.
53. Schiffner R, Schiffner-Rohe J, Wolfl G, Landthaler M, Glassl A, Walther T, et al. Evaluation of a multicentre study of synchronous application of narrowband ultraviolet B phototherapy (TL-01) and bathing in Dead Sea salt solution for psoriasis vulgaris. Br J Dermatol 2000; 142: 740-777.
54. Katzburg JR, Yano EM, Washington DL, Farmer MM, Yee EF, Fu S, et al. Combining women's preferences and expert advice to design a tailored smoking cessation program. Subst Use Misuse 2009; 44: 2114-2137.
55. Sanelli PC, Gold RL, Greenberg ED, Reichman MB, Ugorec I, Segal AZ, et al. Work-in-progress toward incorporating patients' preferences in practice guidelines for imaging aneurysmal subarachnoid hemorrhage. Acad Radiol 2009; 16: 535-540.
56. Auerbach SM, Martelli MF, Mercuri LG. Anxiety, information, interpersonal impacts, and adjustment to a stressful health care situation. J Pers Soc Psychol 1983; 44: 1284-1296.
57. Martelli MF, Auerbach SM, Alexander J, Mercuri LG. Stress management in the health care setting: matching interventions with patient coping styles. J Consult Clin Psychol 1987; 55: 201-207.
58. Gattellari M, Butow PN, Tattersall MH. Sharing decisions in cancer care. Soc Sci Med 2001; 52: 1865-1878.
59. Harvey RM, Kazis L, Lee AF. Decision-making preference and opportunity in VA ambulatory care patients: association with patient satisfaction. Res Nurs Health 1999; 22: 39-48.
60. Heyland DK, Cook DJ, Rocker GM, Dodek PM, Kutsogiannis DJ, Peters S, et al. Decision-making in the ICU: perspectives of the substitute decision-maker. Intens Care Med 2003; 29: 75-82.
61. Keating NL, Guadagnoli E, Landrum MB, Borbas C, Weeks JC. Treatment decision making in early-stage breast cancer: Should surgeons match patients' desired level of involvement? J Clin Oncol 2002; 20: 1473-1479.
62. Ihtatho D, Fadzil MH, Affandi AM, Hussein SH. Area assessment of psoriasis lesion for PASI scoring. Conf Proc IEEE Eng Med Biol Soc 2007; 2007: 3446-3449.
63. Ersser SJ, Surridge H, Wiles A. What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract 2002; 8: 367-376.
64. Lilford RJ, Richardson A, Stevens A, Fitzpatrick R, Edwards S, Rock F, et al. Issues in methodological research: perspectives from researchers and commissioners. Health Technol Assess 2001; 5: 1-57.
65. Bland M. Some problems with sample size: presentation at the Joint Meeting of the Dutch Pathological Society and the Pathological Society of Great Britain & Ireland, Leeds, July 4th, 2008. Available from: http://www-users.york.ac.uk/~mb55/talks/pathsamp.pdf.
66. Crombie IK, Davies HTO. What is meta-analysis? London: Hayward Medical Communications, 2009: p. 8.
67. Health Services Research Group. Studying patients' preferences in health care decision making. CMAJ 1992; 147: 859-864.
68. Torrance GW. Health index and utility models: some thorny issues. Health Serv Res 1973; 8: 12-14.
69. Ciampi A, Silberfeld M, Till JE. Measurement of individual preferences. The importance of "situation-specific" variables. Med Decis Making 1982; 2: 483-495.
70. Naylor CD, Williams JI, Basinski A, Goel V. Technology assessment and cost-effectiveness analysis: misguided guidelines? CMAJ 1993; 148: 921-924.